# Highlights from International Medical Meetings New Directions in the APRIL 11, 2023 Diagnosis and Treatment of Hematologic Cancers

Hematologic malignancies research is growing at a rapid pace, increasing the complexity of the field. Advances in the understanding of the mechanisms of hematologic malignancies have resulted in the development of new prognostic models, novel therapies, and improvements in disease management. It is essential to our community to stay abreast of the latest findings in the field and of their potential impaact on clinical practices.

This symposium will provide attendees with cutting-edge updates and perspectives on new diagnostic tools and management options of hematologic malignancies including genetic profiling, cytogenetics, molecular diagnostics, riskadaptive strategies, and novel therapies recently approved by the FDA. Advances in the understanding of aggressive/ indolent lymphoma, myelodysplasia, plasma cell dyscrasia, acute/chronic leukemia and myeloproliferative disease, will be addressed. Advances in newer therapeutic approaches in classical hematology will be reviewed in the Consultative Hematology section.

### PROGRAM DIRECTOR



Rashmi Khanal, MD Assistant Professor,

Department of Bone Marrow Transplant and Cellular Therapies

### FACULTY



Henry Fung, MD, FACP, FRCPE Chair and Professor, Department of Bone Marrow Transplant and Cellular Therapies

**Peter Abdelmessieh, DO, MSc** Assistant Professor, Department of Bone Marrow Transplant and Cellular Therapies

Associate Professor, Department of Hematology/Oncology
Shazia Nakhoda, MD

Iberia Romina Sosa, MD, PhD

Assistant Professor, Department of Hematology/Oncology

Asya Varshavsky-Yanovsky, MD, PhD Assistant Professor, Department of Bone Marrow Transplant and Cellular Therapies

Marcus Messmer, MD Assistant Professor, Department of Hematology/Oncology

### Michael Styler, MD

Associate Professor, Department of Bone Marrow Transplant and Cellular Therapies

## REGISTER TODAY: FoxChase.org/CME

VIRTUAL CME: Tuesday, April 11, 2023	
5:00 – 9:30 рм EST	Exhibit Hall Open
6:00 – 8:50 рм EST	Education Program
8:50 – 9:20 рм EST	Virtual Q&A Receptior
	& Exhibit Hall

Registration Deadline: Monday, April 10, 2023

### **COMPLIMENTARY REGISTRATION**

Inquiries: Lucía Tono, PhD, MEd 215-728-3797 Lucia.Tono-Ramirez@tuhs.temple.edu

### **LEARNING OBJECTIVES**

After participating in this educational program, learners should be able to:

- Summarize the findings from key clinical trials presented at the 2022 ASH meeting that will impact standards of care in hematology
- Discuss the latest findings in genetic profiling, cytogenetics, and molecular biology, and describe how this information can be utilized in determining patient prognosis and treatment course
- List novel, targeted therapies in development for hematology and explain the therapeutic rationale for these agents
- Describe the latest advances in the field of Consultative Hematology that will impact patient treatment
- Outline how clinical trial data can be efficiently incorporated into community-based hematology practice

### **INTENDED AUDIENCE**

The program is designed for oncologists, hematologists, radiation oncologists, pathologists, internists, primary care physicians, fellows, physician assistants, nurse practitioners, oncology nurses, and social workers.

### **ACCREDITATION STATEMENT**

The Temple Health Office for Continuing Medical Education is accredited by the Pennsylvania Medical Society to provide continuing medical education for physicians.

### **DESIGNATION STATEMENT**

The Temple Health Office for Continuing Medical Education designates this live activity for a maximum of **2.5** *AMA PRA Category 1 Credits*<sup>TM</sup>. Physicians should only claim the credit commensurate with the extent of their participation in the educational activity.

Non-discrimination notice: It is the policy of Fox Chase Cancer Center and Temple University Hospital, Inc., that no one shall be excluded from or denied the benefits of or participation in the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identitylexpression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment. 3/2023